Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label, Multicenter Study to Assess the Safety and Tolerability of MK-1484 as a Monotherapy and in Combination With Pembrolizumab in Adult Participants With Advanced or Metastatic Solid Tumors
Conditions
Interventions
MK-1484
Pembrolizumab
Locations
8
United States
Sanford Cancer Center ( Site 0005)
Sioux Falls, South Dakota, United States
NEXT Oncology ( Site 0001)
San Antonio, Texas, United States
Princess Margaret Cancer Centre-Division of Medical Oncology and Hematology ( Site 0011)
Toronto, Ontario, Canada
Rambam Health Care Campus-Oncology ( Site 0021)
Haifa, Israel
Sheba Medical Center-ONCOLOGY ( Site 0020)
Ramat Gan, Israel
Nederlands Kanker Instituut - Antoni van Leeuwenhoek - NKI-AVL ( Site 0035)
Amsterdam, North Holland, Netherlands
Start Date
June 16, 2022
Primary Completion Date
July 31, 2026
Completion Date
July 31, 2026
Last Updated
November 14, 2024
NCT06307795
NCT06716138
NCT05753722
NCT05581004
NCT07094113
NCT07205718
Lead Sponsor
Merck Sharp & Dohme LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions